Test in Focus
In this episode of “A Test in Focus,” Sanjeev Sethi, M.D., Ph.D., explains Mayo Clinic Laboratories’ new immunohistochemistry assay for the detection of NELL-1 antigen, a biomarker for membranous nephropathy (MN). Identified by Dr. Sethi in 2019, NELL-1 antigen triggers the production of NELL-1 antibodies, which are present in approximately 10% to 15% of MN patients and may be associated with an underlying cancer.
“While many cases of NELL-1 are primary and there’s no disease association, there are multiple studies now that show a subset of NELL-1 positive patients have an underlying malignancy,” Dr. Sethi says. “So if a physician gets a diagnosis of NELL-1 membranous nephropathy, they need to be extra vigilant in screening for hidden malignancies, because it is possible that you treat the malignancy and then the membranous goes away as well.”
Dr. Sethi notes that establishing disease etiology through NELL-1 antigen detection not only enables accurate diagnosis, but elevates treatment outcomes by providing a disease expression on which to base follow-up care.
Listen to learn more about how NELL-1 antigen testing enhances MN diagnosis by equipping providers with specific information on disease manifestation.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Identification of neural epidermal growth factor-like 1 protein (NELL1) primary membranous nephropathy
Patients with elevated LDL or "bad" cholesterol face even greater risk if their levels of small dense LDL cholesterol are also high. Vlad Vasile, M.D., Ph.D., and Leslie Donato, Ph.D., explain how Mayo Clinic Laboratories' sdLDL-c assay measures concentrations of the small dense LDL subtype, to better guide clinical care.
Identifying a precise genetic cause of hearing loss impacts clinical management. Nicole Boczek, Ph.D., and Melanie Meyer, M.S., CGC, explain how Mayo Clinic Laboratories' updated panel yields comprehensive results for optimal patient care.
In this test-specific episode of the "Answers From the Lab" podcast, Wei Shen, Ph.D., explains how Mayo Clinic Laboratories' new breast cancer panel provides rapid results to guide critical decisions about treatment and screening.